Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 28, 2019

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Lipodystrophy AcquiredType1diabetes
Interventions
DRUG

Cyclophosphamide

Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.

Trial Locations (1)

Unknown

RECRUITING

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER